NasdaqCM:VKTXBiotechs
How Viking’s Q4 2025 Earnings and VK2735 Weight-Loss Updates Will Impact Viking Therapeutics (VKTX) Investors
Viking Therapeutics announced it would release its fourth-quarter 2025 results after the market close on February 11, 2026, followed by an earnings call to discuss performance and pipeline progress.
Investor attention is centering on updates for Viking’s weight-loss candidates, including both injectable and oral formulations of VK2735, which could offer future flexibility in how patients receive treatment.
Next, we’ll examine how these anticipated earnings and VK2735 pipeline updates shape...